Trademark: REXADEV 1823520
Word
REXADEV
ID
1823520
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
02 February 2017
Registration Date
02 February 2017
Renewal Date
02 February 2027
Owner(s)
Service
Herbert Smith Freehills
Goods and Services:
Class 5:
Pharmaceutical preparations and biosimilars; pharmaceutical preparations, biosimilars and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations, biosimilars and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations, biosimilars and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behcet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma
Pharmaceutical preparations and biosimilars; pharmaceutical preparations, biosimilars and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations, biosimilars and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal, dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations, biosimilars and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behcet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, Pyoderma Gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancers, asthma, and refractory asthma